[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,641
  • Shares Outstanding, K 6,884
  • Annual Sales, $ 5,210 K
  • Annual Income, $ -22,390 K
  • EBIT $ -19 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.40
  • Price/Sales 4.82
  • Price/Cash Flow N/A
  • Price/Book 2.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.30
  • Most Recent Earnings $-1.05 on 05/15/26
  • Next Earnings Date 08/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.96
  • Number of Estimates 2
  • High Estimate $-0.92
  • Low Estimate $-1.00
  • Prior Year $-0.25
  • Growth Rate Est. (year over year) -284.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +9.01%
on 07/30/26
4.51 -14.19%
on 07/01/26
-0.50 (-11.44%)
since 06/30/26
3-Month
3.55 +9.01%
on 07/30/26
7.30 -46.99%
on 05/21/26
-2.27 (-36.97%)
since 04/30/26
52-Week
2.90 +33.45%
on 04/07/26
23.42 -83.48%
on 10/06/25
-7.56 (-66.15%)
since 07/30/25

Most Recent Stories

More News
Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform

HOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has selected...

PSTV : 3.87 (+6.03%)
CNSY : 3.83 (-0.78%)
Cerenome Launches as an Integrated CNS Oncology Company

HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective...

PSTV : 3.87 (+6.03%)
CNSY : 3.83 (-0.78%)
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central...

PSTV : 3.87 (+6.03%)
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of  Plus Therapeutics, Inc.  (Nasdaq:  PSTV ) (“Plus” or the “Company”), announced today...

PSTV : 3.87 (+6.03%)
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) and Genomic Testing Cooperative, LCA (“GTC”) today announced...

PSTV : 3.87 (+6.03%)
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring

HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network ® (NCCN...

PSTV : 3.87 (+6.03%)
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide ® commercial progress HOUSTON,...

PSTV : 3.87 (+6.03%)
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), announced today that it...

PSTV : 3.87 (+6.03%)
Plus Therapeutics to Provide Business Update Call on June 30, 2026

HOUSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today announced that...

PSTV : 3.87 (+6.03%)
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing...

PSTV : 3.87 (+6.03%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 4.34
2nd Resistance Point 4.14
1st Resistance Point 4.01
Last Price 3.87
1st Support Level 3.68
2nd Support Level 3.48
3rd Support Level 3.35

See More

52-Week High 23.42
Fibonacci 61.8% 15.58
Fibonacci 50% 13.16
Fibonacci 38.2% 10.74
Last Price 3.87
52-Week Low 2.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.